ATE505489T1 - Tgf-beta-1-spezifische antikörper - Google Patents

Tgf-beta-1-spezifische antikörper

Info

Publication number: ATE505489T1
Authority: AT; Austria
Prior art keywords: tgf; beta; specific antibodies; compositions; methods
Prior art date: 2005-04-22

Application number

AT06750860T

Other languages

English (en)

Inventor

Julian Davies

Craig Dickinson

Lihua Huang

Bryan Jones

David Marquis

Scott Rowlinson

Ying Tang

Peter Vaillancourt

Jeffry Watkins

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-22

Filing date

2006-04-20

Publication date

2011-04-15

2006-04-20 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE505489T1 publication Critical patent/ATE505489T1/de

Links

239000000203 mixture Substances 0.000 abstract 2
102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Vascular Medicine (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)

AT06750860T 2005-04-22 2006-04-20 Tgf-beta-1-spezifische antikörper ATE505489T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67408205P	2005-04-22	2005-04-22
PCT/US2006/014943 WO2006116002A2 (en)	2005-04-22	2006-04-20	Tgf beta 1 specific antibodies

Publications (1)

Publication Number	Publication Date
ATE505489T1 true ATE505489T1 (de)	2011-04-15

Family

ID=37192643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06750860T ATE505489T1 (de)	2005-04-22	2006-04-20	Tgf-beta-1-spezifische antikörper

Country Status (23)

Country	Link
US (2)	US7619069B2 (de)
EP (1)	EP1874818B1 (de)
JP (1)	JP5070200B2 (de)
KR (1)	KR100978684B1 (de)
CN (1)	CN101163719A (de)
AT (1)	ATE505489T1 (de)
AU (1)	AU2006240056B2 (de)
BR (1)	BRPI0608376A8 (de)
CA (1)	CA2607448C (de)
CY (1)	CY1111518T1 (de)
DE (1)	DE602006021292D1 (de)
DK (1)	DK1874818T3 (de)
EA (1)	EA016038B1 (de)
ES (1)	ES2361269T3 (de)
HR (1)	HRP20110334T1 (de)
IL (1)	IL186775A (de)
NO (1)	NO20076003L (de)
PL (1)	PL1874818T3 (de)
PT (1)	PT1874818E (de)
RS (1)	RS51845B (de)
SI (1)	SI1874818T1 (de)
UA (1)	UA93201C2 (de)
WO (1)	WO2006116002A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2737519A1 (en) *	2008-09-29	2010-04-01	Centocor Ortho Biotech Inc.	Anti-cd147 antibodies, methods, and uses
CN102272328B (zh) *	2008-11-22	2014-06-18	阿斯图特医药公司	用于诊断和预后肾损伤和肾衰竭的方法和组合物
US8685932B2 (en) *	2008-12-16	2014-04-01	Option Pharmaceuticals, Llc	Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
CA3256587A1 (en)	2009-01-09	2025-05-26	Seagen Inc.	Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
EP2688908B1 (de)	2011-03-23	2017-06-21	Option Pharmaceuticals, LLC	Gezieltes cytokin zur behandlung von muskelskeletterkrankungen
BR112013030958B1 (pt) *	2011-06-03	2022-02-08	Xoma Technology Ltd	Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
US20140302021A1 (en)	2011-10-25	2014-10-09	Onclave Therapeutics Limited	Antibody formulations and methods
DK2822592T3 (en)	2012-03-08	2018-10-15	Ludwig Institute For Cancer Res Limited	TGF-1-SPECIFIC ANTIBODIES AND PROCEDURES AND APPLICATIONS THEREOF
WO2013134665A1 (en)	2012-03-08	2013-09-12	Selig Sealing Products, Inc.	Container sealing member with protected security component and removal tab
DK3489261T3 (da)	2012-08-24	2020-12-14	Univ California	Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
SG10201800800YA (en)	2013-05-06	2018-03-28	Scholar Rock Inc	Compositions and methods for growth factor modulation
AU2015221181B2 (en) *	2014-02-19	2020-08-20	Merck Patent Gmbh	Cancer-targeted IL-12 immunotherapy
SG11201705721WA (en)	2015-01-14	2017-08-30	Brigham & Womens Hospital Inc	Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh) *	2015-03-04	2021-05-11	美商健臻公司	具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh)	2015-03-04	2021-07-21	美商健臻公司	以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CU20180088A7 (es)	2016-02-17	2019-05-03	Novartis Ag	Anticuerpos anti tgfbeta 2
JP7328762B2 (ja) *	2016-02-26	2023-08-17	ザユニヴァーシティオブウェスタンオンタリオ	抗ＣＤ１１ｄ抗体およびその使用
EA201891909A1 (ru) *	2016-03-11	2019-02-28	Сколар Рок, Инк.	TGFβ1-СВЯЗЫВАЮЩИЕ ИММУНОГЛОБУЛИНЫ И ИХ ПРИМЕНЕНИЕ
WO2017201036A1 (en)	2016-05-17	2017-11-23	Genentech, Inc.	Stromal gene signatures for diagnosis and use in immunotherapy
US12281154B2 (en) *	2016-05-20	2025-04-22	President And Fellows Of Harvard College	Gene therapy methods for age-related diseases and conditions
JP7109007B2 (ja)	2016-06-27	2022-07-29	ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア	がん治療の組み合わせ
TW201811827A (zh) *	2016-09-05	2018-04-01	日商中外製藥股份有限公司	抗ＴＧＦ－β１抗體及使用方法
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
CA3060581A1 (en)	2017-05-02	2018-11-08	Merck Sharp & Dohme Corp.	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045086A1 (ja) *	2017-08-29	2019-03-07	林化成株式会社	活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
EP3694552A1 (de)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap-antikörper und verwendungen davon
TW201923089A (zh)	2017-11-06	2019-06-16	美商建南德克公司	癌症之診斷及治療方法
WO2020006516A1 (en)	2018-06-29	2020-01-02	Gensun Biopharma, Inc.	Antitumor immune checkpoint regulator antagonists
CN113164780A (zh)	2018-10-10	2021-07-23	泰洛斯治疗公司	抗lap抗体变体及其用途
MX2021005394A (es)	2018-11-07	2021-07-06	Merck Sharp & Dohme Llc	Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
PH12021551860A1 (en)	2019-01-30	2022-05-16	Scholar Rock Inc	Ltbp complex-specific inhibitors of tgfã and uses thereof
US10851157B2 (en)	2019-07-01	2020-12-01	Gensun Biopharma, Inc.	Antagonists targeting the TGF-β pathway
TW202135862A (zh)	2020-01-11	2021-10-01	美商供石公司	TGFβ抑制劑及其用途
WO2021142448A2 (en)	2020-01-11	2021-07-15	Scholar Rock,Inc.	Tgf-beta inhibitors and use thereof
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
WO2022256723A2 (en)	2021-06-03	2022-12-08	Scholar Rock, Inc.	Tgf-beta inhibitors and therapeutic use thereof
EP4355363A1 (de) *	2021-06-18	2024-04-24	Genzyme Corporation	Anti-tgf-beta-antikörperformulierungen und deren verwendung
WO2023288277A1 (en)	2021-07-14	2023-01-19	Scholar Rock, Inc.	Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023080900A1 (en)	2021-11-05	2023-05-11	Genentech, Inc.	Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en)	2022-10-05	2024-04-11	Genentech, Inc.	Methods and compositions for classifying and treating bladder cancer
EP4599088A1 (de)	2022-10-05	2025-08-13	Genentech, Inc.	Verfahren und zusammensetzungen zur klassifizierung und behandlung von lungenkrebs
WO2024187051A1 (en)	2023-03-07	2024-09-12	Scholar Rock, Inc.	Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en)	2024-05-13	2025-11-20	Scholar Rock, Inc.	Tgf-beta inhibitors for treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US7368111B2 (en) *	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
GB9601081D0 (en)	1995-10-06	1996-03-20	Cambridge Antibody Tech	Specific binding members for human transforming growth factor beta;materials and methods
AU771635B2 (en)	1999-01-05	2004-04-01	American National Red Cross, The	Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en)	1999-01-05	2010-07-27	University Of Utah Research Foundation	Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
JP2006525362A (ja) *	2003-04-30	2006-11-09	ジェンザイムコーポレーション	腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1646655A2 (de) *	2003-07-09	2006-04-19	Eli Lilly And Company	Tgf-beta1 liganden
BRPI0508761A (pt)	2004-03-31	2007-08-14	Genentech Inc	anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
CA2568336A1 (en)	2004-06-04	2005-12-22	Genentech, Inc.	Method for treating lupus
DK1931709T3 (en) *	2005-10-03	2017-03-13	Xencor Inc	FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES

2006
- 2006-04-20 PT PT06750860T patent/PT1874818E/pt unknown
- 2006-04-20 PL PL06750860T patent/PL1874818T3/pl unknown
- 2006-04-20 AT AT06750860T patent/ATE505489T1/de active
- 2006-04-20 HR HR20110334T patent/HRP20110334T1/hr unknown
- 2006-04-20 DE DE602006021292T patent/DE602006021292D1/de active Active
- 2006-04-20 CN CNA2006800135110A patent/CN101163719A/zh active Pending
- 2006-04-20 KR KR1020077024149A patent/KR100978684B1/ko not_active Expired - Fee Related
- 2006-04-20 UA UAA200711364A patent/UA93201C2/ru unknown
- 2006-04-20 WO PCT/US2006/014943 patent/WO2006116002A2/en not_active Ceased
- 2006-04-20 DK DK06750860.6T patent/DK1874818T3/da active
- 2006-04-20 CA CA2607448A patent/CA2607448C/en not_active Expired - Fee Related
- 2006-04-20 EA EA200702278A patent/EA016038B1/ru not_active IP Right Cessation
- 2006-04-20 EP EP06750860A patent/EP1874818B1/de active Active
- 2006-04-20 ES ES06750860T patent/ES2361269T3/es active Active
- 2006-04-20 AU AU2006240056A patent/AU2006240056B2/en not_active Ceased
- 2006-04-20 RS RS20110195A patent/RS51845B/sr unknown
- 2006-04-20 SI SI200631049T patent/SI1874818T1/sl unknown
- 2006-04-20 JP JP2008507883A patent/JP5070200B2/ja not_active Expired - Fee Related
- 2006-04-20 BR BRPI0608376A patent/BRPI0608376A8/pt not_active IP Right Cessation
2007
- 2007-10-18 IL IL186775A patent/IL186775A/en not_active IP Right Cessation
- 2007-10-19 US US11/874,952 patent/US7619069B2/en not_active Expired - Fee Related
- 2007-11-21 NO NO20076003A patent/NO20076003L/no not_active Application Discontinuation
2009
- 2009-10-15 US US12/579,447 patent/US8128927B2/en not_active Expired - Fee Related
2011
- 2011-05-13 CY CY20111100455T patent/CY1111518T1/el unknown

Also Published As

Publication number	Publication date
AU2006240056A1 (en)	2006-11-02
EA200702278A1 (ru)	2008-08-29
PT1874818E (pt)	2011-05-05
CA2607448A1 (en)	2006-11-02
BRPI0608376A8 (pt)	2018-10-16
BRPI0608376A2 (pt)	2010-11-16
KR20070114220A (ko)	2007-11-29
IL186775A0 (en)	2008-02-09
JP5070200B2 (ja)	2012-11-07
NO20076003L (no)	2008-01-22
US20080050375A1 (en)	2008-02-28
US8128927B2 (en)	2012-03-06
IL186775A (en)	2013-03-24
SI1874818T1 (sl)	2011-08-31
EA016038B1 (ru)	2012-01-30
EP1874818A2 (de)	2008-01-09
WO2006116002A9 (en)	2007-07-19
AU2006240056B2 (en)	2012-02-16
HRP20110334T1 (hr)	2011-06-30
KR100978684B1 (ko)	2010-08-31
US20100040633A1 (en)	2010-02-18
DK1874818T3 (da)	2011-06-14
RS51845B (sr)	2012-02-29
UA93201C2 (ru)	2011-01-25
EP1874818B1 (de)	2011-04-13
CY1111518T1 (el)	2015-08-05
PL1874818T3 (pl)	2011-09-30
US7619069B2 (en)	2009-11-17
CN101163719A (zh)	2008-04-16
CA2607448C (en)	2014-11-18
DE602006021292D1 (de)	2011-05-26
WO2006116002A3 (en)	2007-02-01
ES2361269T3 (es)	2011-06-15
WO2006116002A2 (en)	2006-11-02
JP2008538564A (ja)	2008-10-30

Publication	Publication Date	Title
ATE505489T1 (de)	2011-04-15	Tgf-beta-1-spezifische antikörper
CY1124802T1 (el)	2022-11-25	Δεσμευτικοι παραγοντες σκληροστινης
CY2018013I1 (el)	2018-09-05	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
MY174493A (en)	2020-04-23	Binding agents
DK3530673T3 (da)	2022-04-19	Humaniserede anti-beta7-antagonister og anvendelser deraf
DK2135881T3 (da)	2011-12-05	Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
CY1113199T1 (el)	2016-04-13	Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης
MEP35408A (en)	2011-02-10	Tweak binding antibodies
NO20081287A (no)	2008-05-06	Brenselsammensetning og fremgangsmåte for å fremstille denne
DK1836169T3 (da)	2012-03-26	Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
NO20083397L (no)	2008-10-02	Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY1113309T1 (el)	2016-04-13	Συνθεσεις και μεθοδοι χρησιμοποιωντας αντι-cs1 αντισωματα για να θεραπευεται πολλαπλο μυελωμα
DK1817055T3 (da)	2013-04-08	Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf
EA200801174A1 (ru)	2009-02-27	Антитела-миметики glp-2, полипептиды, композиции, способы и применения
NO20083609L (no)	2008-11-12	Fremgangsmater og sammensetninger for malrettet-RELT
IL185653A0 (en)	2008-01-06	Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
MX2007013108A (es)	2008-04-07	Reactivos que enlazan ccx-ckr2.
WO2006008266A3 (en)	2006-08-03	Factor xi-binding proteins
EA202190387A1 (ru)	2022-01-31	Антитело к cd38 человека и его применение
HK1151803B (en)	2015-08-28	Sclerostin binding agents

Legal Events

Date	Code	Title	Description
2011-12-15	UEP	Publication of translation of european patent specification	Ref document number: 1874818 Country of ref document: EP

Date

Code

Title

Description

2011-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1874818

Country of ref document: EP